Download PDF
Digestive Disease Interventions 2017; 01(04): 235-240
DOI: 10.1055/s-0038-1629894
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Medical Management of Portal Hypertension and Its Complications

Tavankit Singh
1   Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio
,
Arthur J. McCullough
1   Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio
2   Department of Pathobiology, Cleveland Clinic Lerner College of Medicine at Case Western University, Cleveland, Ohio
› Author Affiliations
Further Information

Publication History

28 December 2017

03 January 2018

Publication Date:
14 February 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Portal hypertension, most commonly caused by cirrhosis, is defined as an elevated hepatic venous pressure gradient that can lead to complications including ascites, hepatic, esophageal/gastric varices, hepatic encephalopathy, and hepatorenal syndrome. While these complications are initially managed by medical and endoscopic treatments, progressive decompensation of liver disease may lead to liver transplantation.

Keywords

portal hypertension - cirrhosis - medical management
 

  • References

  • 1 Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012; 107 (02) 247-252
    CrossrefPubMedGoogle Scholar
  • 2 Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-C. Deaths: final data for 2009. Natl Vital Stat Rep 2011; 60 (03) 1-116
    PubMedGoogle Scholar
  • 3 Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis?. Hepatology 1997; 25 (01) 245-248
    CrossrefPubMedGoogle Scholar
  • 4 Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008; 134 (06) 1715-1728
    CrossrefPubMedGoogle Scholar
  • 5 Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87 (05) 1120-1126
    CrossrefPubMedGoogle Scholar
  • 6 Pizcueta MP, Piqué JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105 (01) 184-190
    CrossrefPubMedGoogle Scholar
  • 7 Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 (Suppl. 01) S54-S68
    CrossrefPubMedGoogle Scholar
  • 8 Bataller R, Ginès P, Nicolás JM. , et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118 (06) 1149-1156
    CrossrefPubMedGoogle Scholar
  • 9 Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28 (04) 926-931
    CrossrefPubMedGoogle Scholar
  • 10 Gupta TK, Toruner M, Groszmann RJ. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. Digestion 1998; 59 (04) 413-415
    CrossrefPubMedGoogle Scholar
  • 11 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice Guidance by the American Association for the study of liver diseases. Hepatotlogy 2017; 65 (01) 310-335
    PubMedGoogle Scholar
  • 12 Ripoll C, Groszmann R, Garcia-Tsao G. , et al; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133 (02) 481-488
    CrossrefPubMedGoogle Scholar
  • 13 Casado M, Bosch J, García-Pagán JC. , et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114 (06) 1296-1303
    CrossrefPubMedGoogle Scholar
  • 14 Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5 (03) 419-424
    CrossrefPubMedGoogle Scholar
  • 15 Ripoll C, Bañares R, Rincón D. , et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 2005; 42 (04) 793-801
    CrossrefPubMedGoogle Scholar
  • 16 Ginés P, Quintero E, Arroyo V. , et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7 (01) 122-128
    CrossrefPubMedGoogle Scholar
  • 17 Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P. , et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34 (01) 46-52
    CrossrefPubMedGoogle Scholar
  • 18 Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8 (05) 1151-1157
    CrossrefPubMedGoogle Scholar
  • 19 Arroyo V, Bosch J, Mauri M, Ribera F, Navarro-López F, Rodés J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981; 11 (03) 221-229
    CrossrefPubMedGoogle Scholar
  • 20 Bosch J, Arroyo V, Betriu A. , et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78 (01) 92-99
    PubMedGoogle Scholar
  • 21 Witte MH, Witte CL, Dumont AE. Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology 1971; 61 (05) 742-750
    CrossrefPubMedGoogle Scholar
  • 22 Runyon BA. . AASLD PRACTICE GUIDELINE. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis. Hepatology. 2013; 57 (04) 1651-1653
    CrossrefPubMedGoogle Scholar
  • 23 Pérez-Ayuso RM, Arroyo V, Planas R. , et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84 (5 Pt 1): 961-968
    PubMedGoogle Scholar
  • 24 Santos J, Planas R, Pardo A. , et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003; 39 (02) 187-192
    CrossrefPubMedGoogle Scholar
  • 25 Angeli P, Fasolato S, Mazza E. , et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59 (01) 98-104
    CrossrefPubMedGoogle Scholar
  • 26 Angeli P, Dalla Pria M, De Bei E. , et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994; 19 (01) 72-79
    CrossrefPubMedGoogle Scholar
  • 27 Ginés P, Arroyo V, Quintero E. , et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93 (02) 234-241
    CrossrefPubMedGoogle Scholar
  • 28 Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55 (04) 1172-1181
    CrossrefPubMedGoogle Scholar
  • 29 Sersté T, Melot C, Francoz C. , et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52 (03) 1017-1022
    CrossrefPubMedGoogle Scholar
  • 30 Bang UC, Benfield T, Hyldstrup L, Jensen J-EB, Bendtsen F. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver Int 2016; 36 (09) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 31 Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol 2017; 67 (01) 40-46
    CrossrefPubMedGoogle Scholar
  • 32 Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: an update and review of the literature. World J Hepatol 2017; 9 (31) 1197-1204
    CrossrefPubMedGoogle Scholar
  • 33 Abbasi A, Bhutto AR, Alam MT, Aurangzaib M, Masroor M. Frequency of hepatic hydrothorax and its association with Child–Pugh class in liver cirrhosis patients. J Coll Physicians Surg Pak 2016; 26 (07) 566-569
    PubMedGoogle Scholar
  • 34 Sharaf-Eldin M, Bediwy AS, Kobtan A. , et al. Pigtail catheter: a less invasive option for pleural drainage in egyptian patients with recurrent hepatic hydrothorax. Gastroenterol Res Pract 2016; 2016: 4013052
    PubMedGoogle Scholar
  • 35 Coelho-Prabhu N, Kamath PS. Current staging and diagnosis of gastroesophageal varices. Clin Liver Dis 2010; 14 (02) 195-208
    CrossrefPubMedGoogle Scholar
  • 36 Moitinho E, Escorsell A, Bandi JC. , et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117 (03) 626-631
    CrossrefPubMedGoogle Scholar
  • 37 de Franchis R. ; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
    CrossrefPubMedGoogle Scholar
  • 38 Groszmann RJ, Garcia-Tsao G, Bosch J. , et al; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353 (21) 2254-2261
    CrossrefPubMedGoogle Scholar
  • 39 D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131 (05) 1611-1624
    CrossrefPubMedGoogle Scholar
  • 40 Calés P, Oberti F, Payen JL. , et al; French-Speaking Club for the Study of Portal Hypertension. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. Eur J Gastroenterol Hepatol 1999; 11 (07) 741-745
    CrossrefPubMedGoogle Scholar
  • 41 Bhardwaj A, Kedarisetty CK, Vashishtha C. , et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 2017; 66 (10) 1838-1843
    CrossrefPubMedGoogle Scholar
  • 42 Merkel C, Marin R, Angeli P. , et al; Gruppo Triveneto per l'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127 (02) 476-484
    CrossrefPubMedGoogle Scholar
  • 43 Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340 (13) 988-993
    CrossrefPubMedGoogle Scholar
  • 44 Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012; (08) CD004544
    PubMedGoogle Scholar
  • 45 Khuroo MS, Khuroo NS, Farahat KLC, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21 (04) 347-361
    CrossrefPubMedGoogle Scholar
  • 46 Shah HA, Azam Z, Rauf J. , et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol 2014; 60 (04) 757-764
    CrossrefPubMedGoogle Scholar
  • 47 Sarin SK, Wadhawan M, Agarwal SR, Tyagi P, Sharma BC. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005; 100 (04) 797-804
    CrossrefPubMedGoogle Scholar
  • 48 Villanueva C, Colomo A, Bosch A. , et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 49 Wells M, Chande N, Adams P. , et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35 (11) 1267-1278
    CrossrefPubMedGoogle Scholar
  • 50 Hwang JH, Shergill AK, Acosta RD. , et al; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 2014; 80 (02) 221-227
    CrossrefPubMedGoogle Scholar
  • 51 García-Pagán JC, Caca K, Bureau C. , et al; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362 (25) 2370-2379
    CrossrefPubMedGoogle Scholar
  • 52 Albillos A, Zamora J, Martínez J. , et al; Baveno Cooperation. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology 2017; 66 (04) 1219-1231
    CrossrefPubMedGoogle Scholar
  • 53 Trebicka J, Hennenberg M, Laleman W. , et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46 (01) 242-253
    CrossrefPubMedGoogle Scholar
  • 54 Zafra C, Abraldes JG, Turnes J. , et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126 (03) 749-755
    CrossrefPubMedGoogle Scholar
  • 55 Abraldes JG, Villanueva C, Aracil C. , et al; BLEPS Study Group. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150 (05) 1160-1170.e3
    CrossrefPubMedGoogle Scholar
  • 56 Lo EAG, Wilby KJ, Ensom MHH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother 2015; 49 (02) 207-219
    CrossrefPubMedGoogle Scholar
  • 57 Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992; 16 (06) 1343-1349
    CrossrefPubMedGoogle Scholar
  • 58 Ríos Castellanos E, Seron P, Gisbert JP, Bonfill Cosp X. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev 2015; (05) CD010180
    PubMedGoogle Scholar
  • 59 Gentilini P, Laffi G, La Villa G. , et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997; 92 (01) 66-72
    PubMedGoogle Scholar
  • 60 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016; 43 (Suppl. 01) 11-26
    CrossrefPubMedGoogle Scholar
  • 61 Parekh PJ, Balart LA. Ammonia and its role in the pathogenesis of hepatic encephalopathy. Clin Liver Dis 2015; 19 (03) 529-537
    CrossrefPubMedGoogle Scholar
  • 62 Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol 2015; 5 (Suppl. 01) S7-S20
    PubMedGoogle Scholar
  • 63 Watanabe M, Ozaki T, Hirata Y. , et al. Mechanism for lowering blood ammonia levels by lactitol. Jpn J Pharmacol 1995; 67 (04) 369-374
    CrossrefPubMedGoogle Scholar
  • 64 Schiano TD. Treatment options for hepatic encephalopathy. Pharmacotherapy 2010; 30 (5 Pt 2): 16S-21S
    CrossrefPubMedGoogle Scholar
  • 65 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 2016; CD003044
    PubMedGoogle Scholar
  • 66 Di Piazza S, Gabriella Filippazzo M, Valenza LM. , et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23 (07) 403-407
    PubMedGoogle Scholar
  • 67 Mullen KD, Sanyal AJ, Bass NM. , et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12 (08) 1390-7.e2
    CrossrefPubMedGoogle Scholar
  • 68 Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23 (04) 175-178
    PubMedGoogle Scholar
  • 69 Bass NM, Mullen KD, Sanyal A. , et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 70 Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SKA. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108 (09) 1458-1463
    CrossrefPubMedGoogle Scholar
  • 71 Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol 2016; 9 (04) 473-482
    CrossrefPubMedGoogle Scholar
  • 72 Poo JL, Rosas-Romero R, Rodríguez F. , et al. Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City. Dig Dis 1995; 13 (02) 136-142
    CrossrefPubMedGoogle Scholar
  • 73 Rahelić D, Kujundzić M, Romić Z, Brkić K, Petrovecki M. Serum concentration of zinc, copper, manganese and magnesium in patients with liver cirrhosis. Coll Antropol 2006; 30 (03) 523-528
    PubMedGoogle Scholar
  • 74 Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of Hepatic Encephalopathy: A Primer. Ann Pharmacother 2016; 50 (07) 569-577
    CrossrefPubMedGoogle Scholar
  • 75 Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013; 12: 74
    CrossrefPubMedGoogle Scholar
  • 76 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017; CD008716
    PubMedGoogle Scholar
  • 77 Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int 2016; 36 (07) 986-993
    CrossrefPubMedGoogle Scholar
  • 78 Bian J, Wang A, Lin J. , et al. Association between proton pump inhibitors and hepatic encephalopathy: a meta-analysis. Medicine (Baltimore) 2017; 96 (17) e6723
    CrossrefPubMedGoogle Scholar
  • 79 Tsai C-F, Chen M-H, Wang Y-P. , et al. Proton. Gastroenterology 2017; 152 (01) 134-141
    CrossrefPubMedGoogle Scholar
  • 80 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008; 84 (998) 662-670
    CrossrefPubMedGoogle Scholar
  • 81 Israelsen M, Krag A, Allegretti AS. , et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev 2017; 9: CD011532
    PubMedGoogle Scholar
  • 82 Nanda A, Reddy R, Safraz H, Habeeb S, Singal AK. Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2017; ;(Oct): 1
    PubMedGoogle Scholar